Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 rollover clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults enrolled in the prior Phase 2 trial.
A team of researchers at the UCLA School of Dentistry has discovered that nanodiamonds can effectively strengthen a material used for filling teeth during root canal procedures, and can prevent residual infection post treatment.
Protease inhibitors are a class of antiviral drugs that are commonly used to treat HIV, the virus that causes AIDS. Scientists at the University of Nebraska Medical Center designed a new delivery system for these drugs that, when coupled with a drug developed at the University of Rochester School of Medicine and Dentistry, rid immune cells of HIV and kept the virus in check for long periods. The results appear in the journal Nanomedicine: Nanotechnology, Biology and Medicine.
Cerulean Pharma Inc., a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in a trial exploring a dose-intensive schedule for its lead NDC, CRLX101, in patients with advanced solid tumor malignancies.
In a recent breakthrough to combat malaria, a collaboration of Indian and American scientists have identified a malarial parasite protein that can be used to develop antibodies when displayed on novel nanoparticles.
Have a cavity? Ask your dentist about filling it with a mixture of nanoparticles including silica and zirconia. These white fillings (known as nano-composite resins) resemble teeth better than their metal alternatives and are less likely to come loose or fracture teeth.
At the ASTRO 57th Annual Meeting & Exhibition in San Antonio, Texas, Orfit Industries will proudly introduce and demonstrate its "HP PRO SOLUTION", an innovative, comprehensive and versatile immobilization system for use in proton therapy designed for Brain, Head and Neck treatments in proton therapy. The "HP PRO SOLUTION" has received U.S. Food and Drug Administration 510 (k) clearance.
Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, announced today that its Chief Scientific Officer, Takashi Kei Kishimoto, PhD, presented new advancements related to Selecta’s pipeline of novel immunotherapeutic candidates at the 5th Annual American Society for Nanomedicine Meeting in Crystal City, Virginia.
Cerulean Pharma Inc., a clinical stage company developing nanoparticle-drug conjugates (NDCs), today announced completion of enrollment of a randomized Phase 2 trial of its lead NDC, CRLX101, in combination with Avastin®, in third- and fourth-line relapsed renal cell carcinoma (RCC). The trial has enrolled all 110 patients and the company expects to announce top-line data in the first half of 2016.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.